CLDN6 and neoplasm: Preclinical studies in mice revealed a marked increase in proliferating CLDN6-CAR-T cells following treatment with CAR-CLDN6 and subsequent administration of CLDN6-LPX, resulting in complete tumor regression within 14 days.